893736-29-3

Upstream product

• 100-44-7 benzyl chloride 
• 585-76-2 m-bromobenzoic acid 
• 156682-54-1 3-(benzyloxy)phenylboronic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 618-89-3 methyl 3-bromobenzoate 
• 87199-18-6 3-hydroxyphenylboronic acid 
• 53087-13-1 3-(benzyloxy)phenyl bromide 
• 591-20-8 3-Bromophenol 

Relevant academic research and scientific papers

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

With anti-tumor activity of a biphenyl amide compound and its preparation method and application

The invention discloses a diphenyl amide compound with anti-tumor activity as well as a preparation method and an application of the diphenyl amide compound. The structural formula of the compound is shown in the specification, wherein R1 is hydrogen or halogen, R2 is alkoxyl which is substituted by tertiary amino at the tail end and has 1-4 carbon atoms and R2 is connected to the para-position of amide through oxygen atoms. The compound has good inhibiting activity to tumor cells in vitro and can be used for preparing anti-tumor medicines, particularly anti-liver cancer medicines and anti-breast cancer medicines. The preparation method of the diphenyl amide compound has the advantages of easily available raw materials, mild reaction condition, simple reaction operation process and cheap used reagents.

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 μM and 5.98 μM, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors.